Varicella Zoster Virus Envelope Glycoprotein E

Summary

Varicella Zoster Virus Envelope Glycoprotein E (CHEMBL4297975) is an approved vaccine component; indicated across 3 conditions including herpes zoster and respiratory system disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 3 conditions
• Clinical trials: 42

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297975
Name	Varicella Zoster Virus Envelope Glycoprotein E
Type	Vaccine component
Max phase	4

Also known as: Gsk-1437173a, Herpes zoster vaccine gsk1437173a, Shingrix

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
herpes zoster	4	MONDO:0005609	EFO:0006510
respiratory system disorder	2	MONDO:0005087	EFO:0000684

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE3	11
PHASE4	8
PHASE1	8
PHASE2	7
PHASE1/PHASE2	5
EARLY_PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04403139	PHASE4	ACTIVE_NOT_RECRUITING	VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
NCT05170399	PHASE4	RECRUITING	Vaccine Responses in Patients With B Cell Malignancies
NCT05550194	PHASE4	RECRUITING	VZV in the Enteric Nervous System: Pathogenesis and Consequences
NCT06763783	PHASE4	ENROLLING_BY_INVITATION	Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
NCT03591770	PHASE4	TERMINATED	Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib
NCT03798691	PHASE4	COMPLETED	Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab
NCT03886038	PHASE4	COMPLETED	Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)
NCT04169009	PHASE4	COMPLETED	Persistence of Protection by Shingrix
NCT04128189	PHASE3	RECRUITING	Shingrix in Renal Transplant Recipients
NCT01165177	PHASE3	COMPLETED	Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals’ Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older
NCT01165229	PHASE3	COMPLETED	Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
NCT01610414	PHASE3	COMPLETED	Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster Vaccine GSK1437173A
NCT01751165	PHASE3	COMPLETED	Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals’ Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older
NCT01777321	PHASE3	COMPLETED	Safety and Immunogenicity Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years
NCT02058589	PHASE3	COMPLETED	Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant
NCT02690207	PHASE3	COMPLETED	Cross-vaccination Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
NCT02723773	PHASE3	COMPLETED	A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
NCT02735915	PHASE3	COMPLETED	Study to Evaluate Immunogenicity and Safety of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
NCT06001606	PHASE3	UNKNOWN	Immunogenicity, Reactogenicity of Shingrix in SLE
NCT05304351	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
NCT05554068	PHASE2	RECRUITING	Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
NCT05580458	PHASE1/PHASE2	RECRUITING	Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
NCT05701800	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
NCT06569823	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
NCT06581575	PHASE2	ACTIVE_NOT_RECRUITING	A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
NCT06932523	PHASE1/PHASE2	RECRUITING	A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
NCT07205796	PHASE2	NOT_YET_RECRUITING	A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
NCT07481604	PHASE2	NOT_YET_RECRUITING	Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
NCT00802464	PHASE2	COMPLETED	Immunogenicity and Safety Study of GSK Biologicals’ Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
NCT01165203	PHASE2	COMPLETED	Study to Evaluate GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
NCT05703607	PHASE1/PHASE2	TERMINATED	A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
NCT06137755	PHASE1	RECRUITING	Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
NCT06335849	PHASE1	ACTIVE_NOT_RECRUITING	A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
NCT06409494	PHASE1	ACTIVE_NOT_RECRUITING	Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years
NCT07285265	PHASE1	ACTIVE_NOT_RECRUITING	Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
NCT05245838	PHASE1	COMPLETED	Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
NCT05769049	PHASE1	COMPLETED	The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)
NCT05991427	PHASE1	COMPLETED	A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
NCT06375512	PHASE1	COMPLETED	A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
NCT03771157	EARLY_PHASE1	COMPLETED	Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).